CMPI Projected Dividend Yield

Checkmate Pharmaceuticals Inc ( NASDAQ : CMPI )

Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing and commercializing its technology to assist the immune system to combat cancer. Co.'s product candidate, CMP-001, is a Toll-like receptor 9 agonist delivered as a biologic virus-like particle utilizing a cytosine-phosphate-guanine-A oligonucleotide. When injected into a tumor, CMP-001 is designed to trigger the body's innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. Co. is also evaluating CMP-001 across multiple tumor types in combination with other immunotherapy agents.

20 YEAR PERFORMANCE RESULTS